Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Pat...

por Yamashita, Shizuya, Arai, Hidenori, Yokote, Koutaro, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Publicado 2019

Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐...

por Yokote, Koutaro, Yamashita, Shizuya, Arai, Hidenori, Araki, Eiichi, Matsushita, Mitsunori, Nojima, Toshiaki, Suganami, Hideki, Ishibashi, Shun
Publicado 2021

Evaluation of Data Errors and Monitoring Activities in a Trial in Japan Using a Risk-Based Approach Including Central Monitoring and Site Risk Assessment

por Kondo, Hidenobu, Kamiyoshihara, Tomoaki, Fujisawa, Kenji, Nojima, Toshiaki, Tanigawa, Ryohei, Fujiwara, Hisataka, Suganami, Hideki, Hayashi, Yukikazu, Yamaguchi, Takuhiro
Publicado 2021

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty live...

por Nakajima, Atsushi, Eguchi, Yuichiro, Yoneda, Masato, Imajo, Kento, Tamaki, Nobuharu, Suganami, Hideki, Nojima, Toshiaki, Tanigawa, Ryohei, Iizuka, Masakazu, Iida, Yuki, Loomba, Rohit
Publicado 2021